Ligand Pharmaceuticals Inc (LGND) stock
LGNDNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as LGNDZ, LGNXZ, LGNYZ, LGNZZ
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 30, 2026Score 6/30433% above fair value
$293.81−7.90 (-2.62%)
Close on Nov 17, 2026Market cap $5.88BP/E 128.3Yield –
Ligand Pharmaceuticals gross margin
Gross margin is gross profit as a percentage of revenue.
Ligand Pharmaceuticals's gross margin for the twelve months ending Sep 30, 2019 was 91.9%. For fiscal 2018 it was 97.5%, against 96.2% the year before. The highest annual figure on record is 97.5% in fiscal 2018.
Annual gross margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2018 | Dec 31, 2018 | 97.5% | +1.3 |
| FY2017 | Dec 31, 2017 | 96.2% | +1.3 |
| FY2016 | Dec 31, 2016 | 94.9% | +3.0 |
| FY2015 | Dec 31, 2015 | 91.9% | +6.1 |
| FY2014 | Dec 31, 2014 | 85.8% | −2.5 |
| FY2013 | Dec 31, 2013 | 88.3% | −0.2 |
| FY2012 | Dec 31, 2012 | 88.5% | +4.9 |
| FY2011 | Dec 31, 2011 | 83.7% | – |
Quarterly gross margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q3 FY2019 | Sep 30, 2019 | 87.3% | −9.5 |
| Q2 FY2019 | Jun 30, 2019 | 90.4% | −8.4 |
| Q1 FY2019 | Mar 31, 2019 | 91.1% | −7.5 |
| Q4 FY2018 | Dec 31, 2018 | 95.0% | −2.0 |
| Q3 FY2018 | Sep 30, 2018 | 96.8% | +2.0 |
| Q2 FY2018 | Jun 30, 2018 | 98.7% | −0.3 |
| Q1 FY2018 | Mar 31, 2018 | 98.6% | −0.8 |
| Q4 FY2017 | Dec 31, 2017 | 97.1% | +4.7 |
| Q3 FY2017 | Sep 30, 2017 | 94.8% | – |
| Q2 FY2017 | Jun 30, 2017 | 99.0% | – |
| Q1 FY2017 | Mar 31, 2017 | 99.4% | – |
| Q4 FY2016 | Dec 31, 2016 | 92.4% | – |
See a number that looks wrong?